Galectin Therapeutics Inc stock is traded at $2.69, with a volume of 257,651. It is down -4.27% in the last 24 hours and down -21.57% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Previous Close:
$2.81
Open:
$2.80
24h Volume:
257,651
Relative Volume:
1.23
Market Cap:
$271.35M
Revenue:
-
Net Income/Loss:
-$26.25M
P/E Ratio:
-
EPS:
-$0.4099
Net Cash Flow:
-$20.05M
1W Performance:
-11.80%
1M Performance:
-21.57%
6M Performance:
+21.72%
1Y Performance:
-53.14%
1-Day Range:
$2.67$2.93
1-Week Range:
$2.67$3.21
52-Week Range:
$2.03$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
678-620-3186Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS